Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GT Diagnostics is a private health technology and diagnostics company focused on early detection and monitoring of dementia and related cognitive disorders. The company was established in Malaysia as Genting TauRx Diagnostic Centre Sdn Bhd and operates together with its UK subsidiary, GT Diagnostics (UK) Limited, under the GT Diagnostics brand. Its products include HiPAL, a home-based cognitive wellbeing app, and HiPAL Pro, a tablet-based professional assessment tool intended to support clinicians in dementia evaluation and monitoring. The company combines clinical research, digital technology, and workflow integration to provide non-invasive cognitive assessment solutions for use in home, primary care, and specialist settings. GT Diagnostics appears to be commercially active, with products launched in the USA, UK, Malaysia, and parts of Europe.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GT Diagnostics.